Athersys Inc
@athersys
Followers
2,340
Following
738
Media
411
Statuses
1,302
Committed to developing therapies to extend and enhance the quality of human life after stroke and other hard to treat diseases. …
Cleveland, OH
Joined February 2011
Don't wanna be here?
Send us removal request.
Explore trending content on Musk Viewer
#LingOrmFanMeet2geTHer
• 277631 Tweets
DEAR MYLOVE LINGORM
• 272558 Tweets
Edmundo
• 126511 Tweets
#ZeeNunew1stFMinTokyo
• 87164 Tweets
#KPOPMASTERZinBANGKOK2024
• 41914 Tweets
Oregon
• 31426 Tweets
#sbhawks
• 27184 Tweets
京成杯AH
• 25001 Tweets
セントウルS
• 22428 Tweets
アスコリピチェーノ
• 12737 Tweets
メンデス
• 10445 Tweets
FDA authorizes
#Athersys
to initiate a pivotal clinical trial evaluating
#MultiStem
Cell Therapy in patients with
#COVID19
induced
#ARDS
.
9
49
114
Athersys comments on a misleading article authored by hedge fund $ATHX
25
39
98
#Athersys
CEO Gil Van Bokkelen was on
@FoxNews
on
@AmericasNewsroom
sharing the Athersys story about our
#COVID19
induced
#ARDS
program using
#MultiStem
cell therapy. $ATHX
13
41
99
#Athersys
and
@UHhospitals
Announce Activation of the First Clinical Site for the
#MACOVIA
Study, a Pivotal Phase 2/3 Study Evaluating
#MultiStem
Cell Therapy for
#COVID19
Induced
#ARDS
$ATHX
7
33
74
Athersys Announces Commencement of Patient Enrollment in the MACOVIA Study, a Pivotal Phase 2/3 Trial Evaluating MultiStem...
4
26
67
Good news from Japan! Our partner
@HealiosJapan
announced that it has completed enrollment of the
#COVID19
induced
#ARDS
patient cohort which is part of its larger ONE-BRIDGE clinical trial to evaluate the safety of
#MultiStem
® cell therapy in ARDS.
5
29
69
#MultiStem
cell therapy is being evaluated in
#clinicaltrials
for both
#stroke
and
#COVID19
induced
#ARDS
. New evidence suggests there may be correlation due to increased blood clotting.
#StrokeMonth
1
28
68
FDA Authorizes Initiation of a Phase 2 Trial Evaluating
#MultiStem
Cell Therapy in
#Trauma
Patients $ATHX
10
26
67
Congratulations to Dr. Anthony Ting of $ATHX for being appointed as the Chief Commercialization Officer & Chair of the Commercialization Committee at
@ISCTglobal
, a global society of members with a shared vision to drive clinical translation of cell and gene therapies worldwide.
1
20
67
Following the encouraging data from our completed exploratory clinical study of MultiStem® for the treatment of
#ARDS
, we are excited about evaluating the effectiveness of
#MultiStem
for
#COVID19
induced ARDS in the
#MACoVIA
trial.
6
24
62
#DYK
? According to a recent WHO analysis,
#ARDS
is the leading cause of death among
#COVID19
infected patients.
#MultiStem
® is being developed to treat ARDS & other indications. $ATHX
4
19
64
BARDA: Athersys’ Cell Therapy “Highly Relevant” for COVID-19
#coronavirus
#covid19
#MultiStem
$ATHX
#regenerativemedicine
#ARDS
0
32
66
Athersys provides an update on the actions the Company is pursuing related to a short and distort campaign.
9
20
56
Athersys is evaluating
#MultiStem
in a Phase 3
#clinicaltrial
for ischemic stroke. Listen as Dr. David Chiu
@MethodistHosp
explains the need for practical therapies that enhance recovery after a
#stroke
has occurred.
#Stroke36
#StrokeMonth
0
25
60
Cleveland Company Testing Possible Therapy For Deadly COVID-19 Complication on IdeaStream $ATHX
#Athersys
#MultiStem
#ARDS
#COVID19
1
29
54
#Athersys
Announces Positive Results From Its Exploratory Clinical Study of
#MultiStem
® Cell Therapy for Treatment of Acute Respiratory Distress Syndrome (
#ARDS
) $ATHX
4
27
58
FDA Grants RMAT Designation to MultiStem Cell Therapy for the Treatment of Acute Respiratory Distress Syndrome
4
21
58
DYK? According to a recent WHO analysis & other epidemiological data
#ARDS
is the
#1
cause of death among
#COVID19
patients. $ATHX is the only company to have received Fast Track designation from the FDA for the potential treatment of ARDS using
#MultiStem
6
23
51
HEALIOS K.K. Increases Investment in Athersys by Fully Exercising Warrant to Acquire Additional Shares $ATHX
3
21
55
Athersys Appoints Experienced Commercial Leader, Daniel A. Camardo, to Chief Executive Officer
6
13
57
We are pleased to share that
@HealiosJapan
enrolled their first
#COVID19
induced
#ARDS
patient in their clinical study to evaluate the safety of
#MultiStem
® cell therapy. We will continue to work together to develop and evaluate this promising therapeutic.
2
16
54
University Hospitals and Cleveland biotech company Athersys team up for
#COVID19
clinical trial
2
23
54
‘Highly Relevant’ cell therapy for acute corona-related respiratory distress
#regenmed
$ATHX
#COVID19
#MultiStem
1
20
49
MASTERS-2 is possible due to the positive outcomes from MASTERS-1, which showed that patients who received
#MultiStem
treatment ≤36 hrs after stroke onset had a 44% decrease in severe disability & a 56% decrease in mortality.
#StrokeMonth
#ClinicalTrial
#Stroke36
3
9
52
These five
#stroke
survivors have volunteered to share their emotional stories. Listen as they describe their symptoms, their decision to participate in the
#Athersys
MASTERS-1 clinical trial for stroke, and their path to recovery.
#StrokeMonth
2
18
48
Tracking the development of treatments for COVID-19 via
@nbcnews
$ATHX
#Athersys
#MultiStem
#ARDS
#covid19
2
26
47
Athersys Stem Cell Therapy Targets Top Cause of COVID-19 Deaths via
@GENbio
$ATHX
#ARDS
#COVID19
#Athersys
#MultiStem
3
25
48
0
22
51
Athersys Preps
#MultiStem
®
#Stroke
Therapy for Approval Under Japan’s RegenMed Law | BioSpace
0
13
49
$ATHX welcomes Maia Hansen to the executive leadership team as Senior VP of Operations & Supply Chain. Maia will help establish a sustainable supply chain built to enable reliable, cost-effective & best in class commercial manufacturing to support commercial success at Athersys.
4
9
45
Research by Dr. Emily Thompson
@emilythompson88
of
@UniofNewcastle
offers new hope for kidney revival prior to transplantation using
#Athersys
#MultiStem
®
#celltherapy
.
0
19
47
University Hospitals is the first clinical site for
#MultiStem
cell therapy study to combat coronavirus-induced
#ARDS
$ATHX
0
17
45
May is National Stroke Awareness Month. At
#Athersys
we are committed to helping
#stroke
patients and spreading awareness this
#StrokeMonth
. Know the warning signs, learn more here:
1
15
41
Emily Thompson's publication was accepted into the American Journal of Transplantation & full access is now available online. This exciting transplant research was done at Newcastle University using
#MultiStem
cell therapy.
@emilythompson88
@UniofNewcastle
3
22
46
Extended use of mechanical ventilation leads to an increased risk of further medical complications. Topline data from the ONE-BRIDGE study showed that
#ARDS
patients treated with
#MultiStem
spent fewer days on the ventilator than the placebo group.
2
12
44
UH Cleveland Medical Center will be the first clinical site for a new Athersys Inc. trial via
@CrainsCleveland
0
16
42
#Athersys
Announces Enrollment of the First Patient in MASTERS-2 Phase 3 Study of
#MultiStem
Treatment for Ischemic
#Stroke
$ATHX
2
23
41
Important highlights from the topline data of the ONE-BRIDGE study evaluating MultiStem® cell therapy for the treatment of ARDS. We look forward to the next steps as we work with
@HealiosJapan
to move the ARDS program forward in Japan.
0
12
41
Preparing for the commercialization of a completely new and innovative therapy requires careful planning. Meet SIFU, our Secure Integrated Freezer Unit that we have been developing to store and dispense
#MultiStem
vials in pharmacies worldwide.
#ATHXFacts
1
9
41
Our hearts go out to all the people that are being affected by the
#coronavirus
. Some of these patients are developing
#ARDS
. We hope to be in a position to potentially treat future ARDS patients with MultiStem®, our investigational cell therapy. $ATHX
3
23
41
Athersys and HEALIOS K.K. Announce Advancement of Their MultiStem Commercial Partnership
0
10
37
ICYMI: Yesterday we announced the appointment of Daniel A. Camardo as Athersys' new Chief Executive Officer, effective February 14, 2022. We are excited for Dan to join the team and lead us forward on our path to commercialize
#MultiStem
. Welcome, Dan!
2
8
39
Promising preclinical research from the Future Industries Institute of University of South Australia using
#Athersys
#MAPC
® cells suggest that factors produced by the cells may improve
#woundhealing
.
@UniSA
0
18
40
This afternoon Athersys will host the Q1 earnings results conference call. We invite you to listen at 4:30 PM EDT using the webcast link:
1
5
37
$ATHX will present at the Bank of America Merrill Lynch Virtual Healthcare Conference on 5/14 at 8:20 AM EDT. The webcast can be accessed at
0
7
41
Athersys Partner HEALIOS K.K. Announces Positive Topline Results of MultiStem for Acute Respiratory Distress Syndrome in the...
3
12
35
Athersys Reports That Healios Has Completed Enrollment in the ONE-BRIDGE Study of MultiStem for Acute Respiratory Distress ...
4
6
35
Important research published in Stem Cells Translational Medicine by our collaborators at Maastricht UMC+ using
#Athersys
'
#MultiStem
® cell therapy in fetal sheep model suggest the cells protect the cerebellum after asphyxia.
@StemCellsTM
@MaastrichtUMC
0
15
36
A new publication with our Australian collaborators demonstrates the promising effects of MAPC cells for the treatment of burns. Findings show MAPC cells reduced time to healing, decreased inflammation and increased angiogenesis.
0
8
36
UTHealth in Houston and Athersys Announce Commencement of Patient Enrollment in a Phase 2 Trial Evaluating MultiStem Cell T...
2
12
39
Congratulations to our partner Healios on completing enrollment in its TREASURE study in Japan. We are hopeful MultiStem® will help patients suffering from ischemic stroke and look forward to receiving topline results in the future.
#MultiStem
#Stroke
3
10
37
Athersys Receives FDA Agreement Under SPA for Phase III Study of MultiStem® Treatment for Ischemic Stroke $ATHX
0
21
30
HEALIOS K.K. Announces Enrollment of First Patient in Japan in the ONE-BRIDGE Study of
#MultiStem
Treatment for Acute Respiratory Distress Syndrome
#ARDS
$ATHX
0
15
37
#MultiStem
is the only cell therapy program for Acute Respiratory Distress Syndrome
#ARDS
that has both Fast Track and
#RMAT
designation from the FDA.
0
13
35
#Athersys
Announces Fast Track Designation From FDA for
#MultiStem
Program for Acute Respiratory Distress Syndrome $ATHX
#ARDS
1
15
36
0
15
31
Athersys Partner HEALIOS K.K. Completes Enrollment in the TREASURE Study of MultiStem Treatment for Ischemic Stroke
1
7
31
Day 2 of
#ISCT22
! Rochelle Cutrone, Associate Scientist at Athersys presented a poster today titled "Multipotent adult progenitor cells modulate monocyte/macrophage phenotype, cytokine secretion and function."
@ISCTglobal
#biotech
#celltherapy
0
2
35
Dr. Anthony Ting is speaking in two live sessions today at
#ISCT2020
, including the “ISCT CSO Global Showcase on COVID-19” where he will discuss the
#MACOVIA
(MultiStem® Administration for COVID-19 Induced Acute Respiratory Distress Syndrome) trial.
@ISCTglobal
3
11
35
Athersys gets accelerated FDA review for therapy treating most frequent cause of Covid death
0
13
36
#Athersys
will be covering the implications of the
#COVID19
outbreak and the relevance of our programs on our earnings update call taking place on Monday, March 16th at 4:30 PM ET. Please register for the webcast here: $ATHX
#coronavirus
#MultiStem
#ARDS
1
11
30
Athersys gets accelerated FDA review for therapy treating most frequent cause of Covid death via
@Clevlndbizjrnl
0
8
33
Listen as Athersys CFO Mr. Ivor Macleod discusses his years of finance experience and how he is helping
#Athersys
prepare to become a commercialization company on the "Business of Biotech" podcast.
2
14
34
Our deepest sympathies to the family & friends of
@LukePerryIII
, who passed away as a result of a
#stroke
. This is another example of how we need more therapies to treat stroke. Let's change the post-stroke treatment window
#Stroke36
3
6
33
#Athersys
congratulates Dr. Sarah Busch and her fellow honorees in the Crain's 2020 Forty under 40! We commend Sarah for her leadership, dedication and pioneering research related to the use of
#MultiStem
® for treating neurological disease and injury.
0
10
34
On May 21st at 11:00 AM ET Dr. Eric Jenkins from
#Athersys
will speak at the upcoming Alliance for Regenerative Medicine
@alliancerm
webinar titled “Cell Therapy Treatments for
#COVID19
". Register to listen to the free webcast here:
0
12
32
Today we welcome Daniel Camardo to the Athersys team as our new Chief Executive Officer. We are thrilled to have you, Dan! Welcome!
5
7
30
#Athersys
Fourth Quarter and Full Year 2019 Earnings - Company announces
#ARDS
program has been designated by BARDA as a "Highly Relevant" program for
#COVID19
and other pathogens. $ATHX
#coronavirus
#MultiStem
3
15
32
Dr. Anthony Ting and Dr. Robert W. Mays are both presenting this week at this year's Phacilitate Leaders World & World Stem Cell Summit, which brings together the leaders of advanced therapies from all around the world.
#PLW2020
$ATHX
#regenmed
#MultiStem
1
8
31
UTHealth in Houston and
#Athersys
Announce Funding for Clinical Trial using
#MultiStem
to Treat
#Trauma
Patients $ATHX
0
14
27
Featured in BioWorld -
#Athersys
starts pivotal study for
#stemcells
to treat
#COVID19
-induced
#ARDS
0
8
32
Recently, we received approval from the FDA to begin using our bioreactor products in our clinical studies. What is a bioreactor and why is this important? More on this from BJ Lehmann, President and COO of Athersys, below.
0
8
32
Thank you
@CellCultureDish
for featuring
#Athersys
CEO Dr. Gil Van Bokkelen on your podcast to discuss the potential of regenerative medicine and
#MultiStem
cell therapy.
Multistem – A Stable, Off-the Shelf Regenerative Medicine Has Demonstrated Promise in…
0
6
18
0
8
31
Congratulations to Dr. Robert W. Mays
@sayhay66
for being appointed as a member of the Editorial Board of Cytotherapy, the official journal of ISCT. We are honored that this prestigious journal recognizes the integrity of the science being done at
@Athersys
.
@ISCTglobal
$ATHX
2
9
31
Join us on Tuesday, February 16, at 11 AM – 1:30 PM ET for the Athersys Virtual Investor Day. The event will provide investors an overview of the Company’s clinical programs, development progress & commercial manufacturing. Register here:
1
4
30
This is an exciting time to join Athersys, & we’re looking for a skilled Logistics & Supply Chain Specialist/Manager with experience in international cold chain shipping & logistics.
If you or anyone in your network is interested, please send your resume to jobs
@athersys
.com.
3
9
31
Some patients that survive
#ARDS
have trouble getting back to functional independence & the quality of life they once had. If you need support, visit the ARDS Foundation, dedicated to increasing ARDS awareness & supporting patients & families.
@ardsglobal
0
10
32
Promising research by ReGenesys and
@KU_Leuven
published in Stem Cell Research & Therapy suggests xenobiotic-free
#MultiStem
® cells promote wound healing by triggering vascularization.
@stemcellrt
0
14
30
Thank you to all our shareholders and guests that attended the Athersys Investor Day event this morning! $ATHX
7
7
29
Athersys released an educational video to provide additional information about the first-ever clinical study evaluating a cell therapy for the treatment of traumatic injuries. Learn more about MultiStem cell therapy & trauma from the UTHealth clinicians.
0
12
31
Athersys Names Maia Hansen Senior Vice President, Operations and Supply Chain $ATHX
2
9
28
Dr. Alice Valentin-Torres of Athersys discusses the research and findings described in the recent Scientific Reports by Nature publication supporting the hypothesis of how MAPC® (MultiStem®) modulates immune responses under different clinical conditions.
1
11
28
$ATHX is featured today in
@Reuters_Health
about the promising field of regenerative medicine and our Phase 3 trial for treating ischemic stroke with
#MultiStem
.
0
21
27
$ATHX is planning a clinical trial to evaluate our investigational
#MultiStem
cell therapy for the treatment of
#trauma
. With traumatic injury on the rise, new therapies are much needed to treat these patients.
0
8
29
Dr. Robert Mays, Vice President of Regenerative Medicine and Head of Neuroscience Programs at
#Athersys
at
#ISCT2019
discussing the clinical development of
#MultiStem
therapy for acute injuries of the central nervous system. $ATHX
0
8
27
Today starts Respiratory Care Week. We are committed to treating Acute Respiratory Distress Syndrome
#ARDS
and other severe inflammatory conditions with our stem cell therapy
#MultiStem
. Learn more here:
0
8
29
#DYK
? 25 years ago, the first data on tPA was presented. Today, we need more options for
#stroke
treatment and MultiStem
#CellTherapy
is being evaluated in Phase 3 clinical trials for the treatment of
#ischemicstroke
.
Listen to
@UTHealth
Dr. Savitz to learn more here:
0
9
27